{
    "clinical_study": {
        "@rank": "97667", 
        "brief_summary": {
            "textblock": "RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver\n      tumor-killing substances to them without harming normal cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody in treating\n      children with metastatic neuroblastoma in second remission."
        }, 
        "brief_title": "Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission", 
        "completion_date": {
            "#text": "September 2001", 
            "@type": "Actual"
        }, 
        "condition": "Neuroblastoma", 
        "condition_browse": {
            "mesh_term": "Neuroblastoma"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Evaluate the efficacy of ganglioside GD2-specific monoclonal antibody 3F8 as\n      adjuvant therapy in patients with Stage IV neuroblastoma in second remission.\n\n      OUTLINE: Biological Response Modifier Therapy. Antiganglioside GD2-specific Monoclonal\n      Antibody 3F8, MOAB 3F8.\n\n      PROJECTED ACCRUAL: A maximum of 20 patients will be entered."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Histologically confirmed, Stage IV neuroblastoma in second or\n        subsequent complete remission, defined by the complete disappearance of all evidence of\n        tumor on the following: Physical examination Second-look surgery Bone scan Bone marrow\n        aspiration and biopsy Chest x-ray CT MIBG Urinary catecholamines If marrow is infiltrated\n        by tumor, complete elimination of tumor cells from the marrow compartment must be\n        demonstrated by histology and immunofluorescence (based on simultaneous bone marrow\n        aspiration and biopsy samples from at least 4 separate sites)\n\n        PATIENT CHARACTERISTICS: Age: Under 18 Performance status: Not specified Life expectancy:\n        Greater than 12 weeks Hematopoietic: Grade 4 cytopenias allowed Grade 3 marrow hypoplasia\n        allowed Hepatic: Not specified Renal: No renal dysfunction worse than grade 3\n        Cardiovascular: No cardiac dysfunction worse than grade 2 Pulmonary: No pulmonary\n        dysfunction worse than grade 2 Other: No neurologic dysfunction worse than grade 2 Hearing\n        deficit allowed\n\n        PRIOR CONCURRENT THERAPY: Prior murine antibody therapy allowed provided circulating HAMA\n        titer is less than 1,000 U/mL serum by ELISA"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002458", 
            "org_study_id": "87-118", 
            "secondary_id": [
                "CDR0000075103", 
                "NCI-V88-0357"
            ]
        }, 
        "intervention": {
            "intervention_name": "monoclonal antibody 3F8", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins", 
                "Antibodies, Monoclonal"
            ]
        }, 
        "keyword": [
            "disseminated neuroblastoma", 
            "recurrent neuroblastoma"
        ], 
        "lastchanged_date": "June 4, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MSKCC-87118"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "Memorial Sloan-Kettering Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Study of Adjuvant Therapy With Antiganglioside GD2-Specific Mouse Monoclonal Antibody 3F8 for Metastatic Neuroblastoma in Second Remission", 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Nai-Kong V. Cheung, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2001", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002458"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 1987", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }, 
    "geocoordinates": {
        "Memorial Sloan-Kettering Cancer Center": "40.714 -74.006"
    }
}